LECALPIN

This brand name is authorized in Ireland, Poland.

Active ingredients

The drug LECALPIN contains one active pharmaceutical ingredient (API):

`1`	Lercanidipine UNII `OA8TFX68PE` - LERCANIDIPINE HYDROCHLORIDE
	Lercanidipine is a calcium antagonist of the dihydropyridine group and inhibits the transmembrane influx of calcium into cardiac and smooth muscle. The mechanism of its antihypertensive action is due to a direct relaxant effect on vascular smooth muscle thus lowering total peripheral resistance.
	Read more about Lercanidipine

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
C08CA13	Lercanidipine	C Cardiovascular system → C08 Calcium channel blockers → C08C Selective calcium channel blockers with mainly vascular effects → C08CA Dihydropyridine derivatives
Discover more medicines within C08CA13

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
IE	Health Products Regulatory Authority	26004, 26005
PL	Rejestru Produktów Leczniczych	100225121, 100225138, 100327614, 100327620, 100338285, 100338552, 100348272, 100348303, 100349811, 100350978, 100393195, 100408583, 100408614, 100412395, 100414052, 100452524, 100452563

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.